FOS and diffuse large B-cell lymphoma: We combined the c‐Fos inhibitors T‐5224 and CDF with LAQ824, and CCK8 assays showed a more substantial killing effect on different DLBCL cell lines than LAQ824 monotherapy (CI<1) (Figure 4I, Figure S5B, and Table S1).